Selected List of publications

Rehavi, M., Maayani, S. and Sokolovsky, M. (1977). Tricyclic antidepressants as antimuscarinic drugs: in vivo and in vitro studies. Biochemical Pharmacology, 26:1559-1567.

Rehavi, M. and Sokolovsky, M. (1978). Multiple binding sites of tricyclic antidepressant drugs to mammalian brain receptors. Brain Research, 149:525-529.

Paul, S.M., Rehavi, M., Skolnick, P. and Goodwin, F.K. (1980). Demonstation of specific “high affinity” binding sites for [3H]imipramine on human platelets. Life Sciences, 26:953-959.

Rehavi, M., Paul, S.M. Skolnick, P. and Goodwin F.K. (1980). Demonstration of specific high affinity binding sites for [3H]imipramine in human brain. Life Sciences, 26:2273-2279.

Paul, S.M., Rehavi, M., Rice, K.C., Ittah, Y. and Skolnick, P. (1981). Does high affinity [3H]imipramine binding label serotonin reuptake sites in brain and in platelets? Life Sciences, 28:2753-2760.

Rehavi, M., Skolnick, P., Hulihan, B., and Paul, S.M. (1981). “High affinity” binding of [3H]desipramine to rat cerebral cortex: relationship to tricyclic antidepressent-induced inhibition of norepinephrine uptake. European Journal of Pharmacology, 70:597-599.

Paul, S.M., Rehavi, M., Skolnick, P., Ballenger, J.C. and Goodwin, F.K. (1981). Depressed patients have decreased binding of [3H]imipramine to the platelet serotonin tranporter. Archives of General Psychiatry, 38:1315-1317.

Rehavi, M., Skolnick, P., Brownstein, M.J. and Paul, S.M. (1982). High affinity binding of [3H]desipramine to rat brain-a presynaptic marker for noradrenergic uptake sites. J. Neurochemistry, 38:889-895.

Rehavi, M., Skolnick, P. and Paul, S.M. (1983). Subcellular distribution of high affinity [3H]imipramine binding and [3H]serotonin uptake in rat brain. European Journal of Pharmacology, 87:335-339.

Rehavi, M., Weizman, R., Carel, C., Apter, A. and Tyano, S. (1984). High affinity [3H]imipramine binding in platelets of children and adolescents with major affective disorder. Psychiatry Research, 13:31-39.

Weizman, A., Carmi, M., Hermesh, H., Shahar, A., Apter, A., Tyano, S. and Rehavi, M. (1986). High affinity imipramine binding and serotonin uptake in platelets of adolescents and adult obsessive compulsive patients. The American Journal of Psychiatry, 143;335-339.

Rehavi, M., Sepcuti, H, and Weizman, A. (1987). Upregulation of imipramine binding and serotonin uptake by estradiol in female rat brain. Brain Research, 410:135-139.

Ginns, E.I., Rehavi, M., Martin, B.M., Weller, M., O’Malley, L., LaMarca, M.E., McAllister, C.G. and Paul, S.M. (1988). Expression of human tyrosine hydroxylase cDNA in invertebrate cells using a Baculovirus vector. The Journal of Biological Chemistry, 263:7406-7410.

Rehavi, M., Carmi, R. and Weizman, A. (1988). Tricyclic antidepressants and calcium channel blockers: interaction at the (-) desmethoxyverapamil binding site and the serotonin transporter. European Journal of Pharmacology, 155:1-9.

Weizman, R., Gil-Ad, I., Karp, L., Laor, N., Barber, Y., and Rehavi, M. (1992). Platelet imipramine binding and plasma cortisol levels in Israeli civilians during the Gulf War. Biological Psychiatry, 32:170-178.

Rehavi, M., Jerushalmi, Z., Aviv, A., Laor, N., Podliszewski, E., Karp, L., Shavit, S. and Weizman, R. (1993). Interaction between antidepressants and phosphoinositide signal transduction system in human platelets. Biological Psychiatry, 33:40-44.

Gordon, I., Rehavi, M. and Mintz, M. (1994). Bilateral imbalance in striatal DA uptake controls rotation behavior. Brain Research, 646:207-210.

Gordon, I., Weizman, R., and Rehavi, M. (1994). [3H]GBR 12935 binding to human platelet membranes is sensitive to piperazine derivatives but not to dopamine uptake inhibitors. Life Sciences, 55:189-199.

Gordon, I., Weizman, R. and Rehavi, M. (1995). [3H]GBR 12935 labels mainly the piperazine acceptor site in the rat prefrontal cortex. Brain Research, 674:205-210.

Eyal, S., Weizman, A., Toren, P., Dor, J., Mester, R. and Rehavi, M. (1996). Chronic GnRH agonist administration down-regulates platelet serotonin transporter in women undergoing assisted reproductive technology. Psychopharmacology, 125:141-145.

Attali, G., Weizman, A., Gil-Ad, I. and Rehavi, M. (1997). Opposite modulatory effects of ovarian hormones on rat brain dopamine and serotonin transporters. Brain Res. 756:153-159.

Rehavi, M., Goldin, M., Roz, N. and Weizman, A. (1998). Regulation of rat brain vesicular monoamine transporter (VMAT₂) by chronic treatment with ovarian hormones,  Molecular Brain Research, 57:31-37.

Zucker, M., Weizman, A. and Rehavi, M. ( 2001). Characterization of high-affinity [³H]TBZOH binding to the human platelet vesicular monoamine transporter. Life Sciences, 69:2311-2317.

Rehavi, M., Roz, N., Weizman, A. (2002). Chronic clozapine, but not haloperidol, treatment affects rat brain vesicular monoamine transporter 2. Eur Neuropsychopharmacol., 12(3):261-8.

Zucker, M., Valevski, A., Weizman, A., Rehavi, M. (2002). Increased platelet vesicular monoamine transporter density in adult schizophrenia patients. Eur Neuropsychopharmacol., 12(4):343-7.

Roz, N., Mazur, Y., Hirshfeld, A., Rehavi, M. (2002). Inhibition of vesicular uptake of monoamines by hyperforin. Life Sci. 27;71(19):2227.

Roz, N., Rehavi, M. (2003). Hyperforine inhibits vesicular uptake of monoamines by dissipating the pH gradient across synaptic vesicle membrane. Life Sciences, 73: 461-470.

Barkan, T., Gurwitz, D., Levy, G., Weizman, A., Rehavi, M. (2004). Biochemical and pharmacological characterization of the serotonin transporter in human peripheral blood lymphocytes. European Neuropsychopharmacology, 14: 237-243.

Roz, N., Rehavi, M. (2004). Hyperforin deplets synaptic vesicles content and induces compartemental redistribution of nerve ending monoamines. Life Sciences, 75: 2841-2850.

Joel, D., Doljansky, J. Roz, N., Rehavi, M. (2005). Role of orbital cortex and of the serotonergic system in a rat model of obsessive compulsive disorder. Neuroscience, 130: 25-36.

Schwartz, K., Weizman, A. and Rehavi, M. (2005). The effect of psychostimulants on [³H]dopamine uptake and release in rat brain synaptic vesicles. J. Neural Trans.  113: 1347-1352.

Schwartz, K., Herman, I., Peer, G., Weizman, A., and Rehavi, M. (2006). Elevated platelet vesicular monoamine transporter 2 in former heroin addicts maintained on methadone. J. Neural. Transm. 114: 281-284.

Schwartz, K., Nachman, R., Yossifoff m., Sapir,R., Weizman, A. and Rehavi, M. (2007). Cocaine, but not amphetamine, short term treatment  elevates the density of the vesicular monoamine transporter 2 in rat brain. J. Neural. Transm.  114: 427-430.

Shabat-Simon, M., Levy, D., Amir, A., Rehavi, M., and Zangen, A. (2008). Dissociation between rewarding and psychomotor effects of opiates: differential roles for glutamate receptors within anterior and posterior portions of the ventral tegmental area.  J Neurosci 28, 8406-8416.

Reichenstein, M., Rehavi, M., and Pinhasov, A. (2008). Involvement of pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors in the mechanism of antidepressant action. J Mol Neurosci 36, 330-338.

Malkoff, A., Weizman, A., Gozes, I., and Rehavi, M. (2008). Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol. J Neural Transm 115, 1563-1571.

Eliash, S., Dror, V., Cohen, S., and Rehavi, M. (2009). Neuroprotection by rasagiline in thiamine deficient rats. Brain Res 1256, 138-148.

Dror, V., Eliash,S., Rehavi ,M., Assaf,Y., Biton,IE., and Fattal-Valevski, A. (2010). Neurodegeneration in a thiamine deficient rats- a longitudinal MRI study. Brain Res. 1308, 176-184

Morag, A., Kirchheiner, J., Rehavi, M., and Gurwitz, D. (2010). Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathways. Pharmacogenomics 11, 327-340.

Simchon, Y., Weizman, A., and Rehavi, M. (2010). The effect of methylphenidate administration on presynaptic dopaminergic parameters in a rat model for ADHD. Eur. Neuropsychopharmacol. 20, 714-720.

Bismuth-Evenzal, Y., Roz, N., Gurwitz, D., and Rehavi, M. (2010). N-methyl-Citalopram: A quaternary  selective serotonin uptake inhibitor. Biochem. Pharmacol. 80, 1546-1552.